IMUC - ImmunoCellular Therapeutics, Ltd.

NYSE American - NYSE American Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201712/31/201612/31/2015
Total Revenue---
Cost of Revenue---
Gross Profit---
Operating Expenses
Research Development17,126.24419,105.72710,896.591
Selling General and Administrative4,027.25,006.3984,616.5
Non Recurring---
Others---
Total Operating Expenses---
Operating Income or Loss-21,153.444-24,112.125-15,513.091
Income from Continuing Operations
Total Other Income/Expenses Net7,724.123,836.7792,945.121
Earnings Before Interest and Taxes-13,429.324-20,275.346-12,567.97
Interest Expense882.6831,810.356222.844
Income Before Tax-14,312.007-22,085.702-12,790.814
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-14,312.007-22,085.702-12,790.814
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-14,312.007-22,085.702-12,790.814
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-17,681.653-22,085.702-12,790.814